New HIV pill dose for kids shows promise in african study
NCT ID NCT05993767
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new combination of three HIV drugs (dolutegravir, emtricitabine, and tenofovir alafenamide) in 53 children aged 28 days to 10 years in Africa. The goal was to find a dose that gives enough medicine in the blood and is safe. If it works, this could lead to a single, easy-to-take pill for children living with HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dolutegravir, emtricitabine, and tenofovir alafenamide (three anti-HIV drugs combined)
What this could lead to
If successful, this could lead to a simpler, child-friendly pill that helps control HIV in children across Africa.
What could go wrong
This is a small, early-phase study (53 children) focused on drug levels and safety, not on long-term cure. The new dose may not work for all children or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine Children's Foundation
Kampala, Uganda
-
Joint Research Centre
Kampala, Uganda
-
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe